New drugs for ALS: How do we get there?

Glass, Jonathan D.

doi:10.1016/j.expneurol.2011.10.007

Cited by 7 publications

(2 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One potential limitation in the development of new therapeutics targeting ALS is the observed discordance between interventions that demonstrate activity in ALS animal models and efficacy in the clinical setting. The reasons for this discrepancy are manyfold and have been highlighted elsewhere and are therefore not in the scope for this review [173]. As a potential mechanism for mitigating this issue, a drug repositioning approach has been suggested [173].…”

Section: Activation Of Autophagy and The Ups For Protein Clearancementioning

confidence: 99%

“…The reasons for this discrepancy are manyfold and have been highlighted elsewhere and are therefore not in the scope for this review [173]. As a potential mechanism for mitigating this issue, a drug repositioning approach has been suggested [173]. This approach would test as many FDA approved drugs as possible, in a small number of patients to observe if a marked clinical benefit was noted in individual patients.…”

Section: Activation Of Autophagy and The Ups For Protein Clearancementioning

confidence: 99%

See 1 more Smart Citation

Emerging drug targets in amyotrophic lateral sclerosis

Bova

Kinney

2012

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

Introduction: Amyotrophic lateral sclerosis (ALS) is a progressive and devastating neurodegenerative disease resulting from injury and death of upper and lower motor neurons. Symptoms initially include muscle weakness and twitching and subsequently progress to muscle atrophy, complete loss of limb use, respiratory difficulties and ultimately death. Multiple biological mechanisms have been implicated in ALS and a complex etiology has been described. As a result, drug discovery researchers have few validated targets to pursue and patients have few therapeutic options. Areas covered: Identification of new drug targets in ALS can be facilitated by a detailed understanding of the processes and genes that contribute to pathogenesis. Accordingly, this review summarizes current hypotheses regarding underlying mechanisms for motor neuron susceptibility in ALS. An overview of emerging and tractable drug targets that could result in therapeutic breakthroughs is provided. Expert opinion: Despite the immense progress that has been made in understanding ALS over the last decade, riluzole remains the only approved drug to treat ALS. Combining structure-guided drug design applied to validated and pharmaceutically tractable targets with disease-relevant phenotypic screens will allow for the identification of novel drug targets and potentially breakthrough therapeutics for ALS.

show abstract

Section: Activation Of Autophagy and The Ups For Protein Clearancementioning

confidence: 99%

Section: Activation Of Autophagy and The Ups For Protein Clearancementioning

confidence: 99%